

Dai Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/318959/publications.pdf>

Version: 2024-02-01

47
papers

3,216
citations

230014

27
h-index

242451

47
g-index

52
all docs

52
docs citations

52
times ranked

3072
citing authors

#	ARTICLE	IF	CITATIONS
1	Structural basis for HCMV Pentamer recognition by neuropilin 2 and neutralizing antibodies. <i>Science Advances</i> , 2022, 8, eabm2546.	4.7	8
2	A novel high throughput assay to quantify Epstein-Barr virus neutralizing antibody activity against B-cell and epithelial cell infections for vaccine and therapeutic developments. <i>Vaccine</i> , 2022, 40, 3638-3646.	1.7	1
3	Polymorphic Forms of Human Cytomegalovirus Glycoprotein O Protect against Neutralization of Fibroblast Entry by Antibodies Targeting Epitopes Defined by Glycoproteins H and L. <i>Viruses</i> , 2022, 14, 1508.	1.5	1
4	Functional Evaluation and Genetic Evolution of Human T-Cell Responses After Vaccination With a Conditionally Replication-Defective Cytomegalovirus Vaccine. <i>Journal of Infectious Diseases</i> , 2021, 223, 2001-2012.	1.9	7
5	Potent Bispecific Neutralizing Antibody Targeting Glycoprotein B and the gH/gL/pUL128/130/131 Complex of Human Cytomegalovirus. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	10
6	Generation of SARS-CoV-2 reporter replicon for high-throughput antiviral screening and testing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	64
7	A conditionally replication-defective cytomegalovirus vaccine elicits potent and diverse functional monoclonal antibodies in a phase I clinical trial. <i>Npj Vaccines</i> , 2021, 6, 79.	2.9	19
8	The Role of Congenital Cytomegalovirus Infection in Adverse Birth Outcomes: A Review of the Potential Mechanisms. <i>Viruses</i> , 2021, 13, 20.	1.5	28
9	Novel adjuvants enhance immune responses elicited by a replication-defective human cytomegalovirus vaccine in nonhuman primates. <i>Vaccine</i> , 2021, 39, 7446-7456.	1.7	9
10	Recognition of a highly conserved glycoprotein B epitope by a bivalent antibody neutralizing HCMV at a post-attachment step. <i>PLoS Pathogens</i> , 2020, 16, e1008736.	2.1	17
11	Specificity and effector functions of non-neutralizing gB-specific monoclonal antibodies isolated from healthy individuals with human cytomegalovirus infection. <i>Virology</i> , 2020, 548, 182-191.	1.1	11
12	Antibody binding to native cytomegalovirus glycoprotein B predicts efficacy of the gB/MF59 vaccine in humans. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	37
13	The Status of Vaccine Development Against the Human Cytomegalovirus. <i>Journal of Infectious Diseases</i> , 2020, 221, S113-S122.	1.9	73
14	Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection. <i>Npj Vaccines</i> , 2020, 5, 16.	2.9	109
15	Phase 1 Clinical Trial of a Conditionally Replication-Defective Human Cytomegalovirus (CMV) Vaccine in CMV-Seronegative Subjects. <i>Journal of Infectious Diseases</i> , 2019, 220, 411-419.	1.9	48
16	Identification of adipocyte plasma membrane-associated protein as a novel modulator of human cytomegalovirus infection. <i>PLoS Pathogens</i> , 2019, 15, e1007914.	2.1	13
17	Neutralizing Monoclonal Antibodies Reduce Human Cytomegalovirus Infection and Spread in Developing Placentas. <i>Vaccines</i> , 2019, 7, 135.	2.1	24
18	A Replication-Defective Human Cytomegalovirus Vaccine Elicits Humoral Immune Responses Analogous to Those with Natural Infection. <i>Journal of Virology</i> , 2019, 93, .	1.5	32

#	ARTICLE	IF	CITATIONS
19	Targeting Human-Cytomegalovirus-Infected Cells by Redirecting T Cells Using an Anti-CD3/Anti-Glycoprotein B Bispecific Antibody. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	15
20	Neutralization of Diverse Human Cytomegalovirus Strains Conferred by Antibodies Targeting Viral gH/gL/pUL128-131 Pentameric Complex. <i>Journal of Virology</i> , 2017, 91, .	1.5	60
21	Functionally inactivated dominant viral antigens of human cytomegalovirus delivered in replication incompetent adenovirus type 6 vectors as vaccine candidates. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2763-2771.	1.4	4
22	Impact of Antibodies and Strain Polymorphisms on Cytomegalovirus Entry and Spread in Fibroblasts and Epithelial Cells. <i>Journal of Virology</i> , 2017, 91, .	1.5	35
23	A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge. <i>Journal of Virology</i> , 2017, 91, .	1.5	30
24	Genetic Stability of Parainfluenza Virus 5-Vectored Human Respiratory Syncytial Virus Vaccine Candidates after <i>In Vitro</i> and <i>In Vivo</i> Passage. <i>Journal of Virology</i> , 2017, 91, .	1.5	14
25	Parainfluenza Virus 5 Expressing Wild-Type or Prefusion Respiratory Syncytial Virus (RSV) Fusion Protein Protects Mice and Cotton Rats from RSV Challenge. <i>Journal of Virology</i> , 2017, 91, .	1.5	21
26	Complement enhances <i>in vitro</i> neutralizing potency of antibodies to human cytomegalovirus glycoprotein B (gB) and immune sera induced by gB/MF59 vaccination. <i>Npj Vaccines</i> , 2017, 2, 36.	2.9	39
27	Active evolution of memory B-cells specific to viral gH/gL/pUL128/130/131 pentameric complex in healthy subjects with silent human cytomegalovirus infection. <i>Oncotarget</i> , 2017, 8, 73654-73669.	0.8	28
28	A replication-defective human cytomegalovirus vaccine for prevention of congenital infection. <i>Science Translational Medicine</i> , 2016, 8, 362ra145.	5.8	87
29	Functional analysis of human cytomegalovirus UL/bâ€² region using SCID-hu mouse model. <i>Journal of Medical Virology</i> , 2016, 88, 1417-1426.	2.5	7
30	Preclinical evaluations of peptide-conjugate vaccines targeting the antigenic domain-2 of glycoprotein B of human cytomegalovirus. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2106-2112.	1.4	20
31	Soluble Human Cytomegalovirus gH/gL/pUL128â€“131 Pentameric Complex, but Not gH/gL, Inhibits Viral Entry to Epithelial Cells and Presents Dominant Native Neutralizing Epitopes. <i>Journal of Biological Chemistry</i> , 2015, 290, 15985-15995.	1.6	40
32	Progress on pursuit of human cytomegalovirus vaccines for prevention of congenital infection and disease. <i>Vaccine</i> , 2014, 32, 2525-2533.	1.7	76
33	Progress on human cytomegalovirus vaccines for prevention of congenital infection and disease. <i>Current Opinion in Virology</i> , 2014, 6, 13-23.	2.6	36
34	Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E4997-5005.	3.3	116
35	Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus. <i>Vaccine</i> , 2012, 30, 7469-7474.	1.7	61
36	A novel high-throughput neutralization assay for supporting clinical evaluations of human cytomegalovirus vaccines. <i>Vaccine</i> , 2011, 29, 8350-8356.	1.7	31

#	ARTICLE	IF	CITATIONS
37	Quantitative analysis of neutralizing antibody response to human cytomegalovirus in natural infection. <i>Vaccine</i> , 2011, 29, 9075-9080.	1.7	61
38	Human cytomegalovirus suppresses type I interferon secretion by plasmacytoid dendritic cells through its interleukin 10 homolog. <i>Virology</i> , 2009, 390, 330-337.	1.1	56
39	Human cytomegalovirus uses two distinct pathways to enter retinal pigmented epithelial cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 20037-20042.	3.3	72
40	Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 18153-18158.	3.3	435
41	Human Cytomegalovirus UL131 Open Reading Frame Is Required for Epithelial Cell Tropism. <i>Journal of Virology</i> , 2005, 79, 10330-10338.	1.5	309
42	Identification of Proteins in Human Cytomegalovirus (HCMV) Particles: the HCMV Proteome. <i>Journal of Virology</i> , 2004, 78, 10960-10966.	1.5	521
43	Human cytomegalovirus encodes a highly specific RANTES decoy receptor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 16642-16647.	3.3	110
44	The VP1 N-Terminal Sequence of Canine Parvovirus Affects Nuclear Transport of Capsids and Efficient Cell Infection. <i>Journal of Virology</i> , 2002, 76, 1884-1891.	1.5	125
45	Canine and Feline Parvoviruses Can Use Human or Feline Transferrin Receptors To Bind, Enter, and Infect Cells. <i>Journal of Virology</i> , 2001, 75, 3896-3902.	1.5	209
46	A Heterogeneous Nuclear Ribonucleoprotein A/B-Related Protein Binds to Single-Stranded DNA near the 5' End or within the Genome of Feline Parvovirus and Can Modify Virus Replication. <i>Journal of Virology</i> , 1999, 73, 7761-7768.	1.5	23
47	Nonstructural Protein-2 and the Replication of Canine Parvovirus. <i>Virology</i> , 1998, 240, 273-281.	1.1	53